Methylation of 14-3-3-σ gene and prognostic significance of 14-3-3-σ expression in non-small cell lung cancer

PRITSANA RAUNGRUT, PINGPOND PETJAROEN, SARAYUT LUCIEN GEATER, WARANGKANA KEERATCHANANONT, MONLIKA PHUKAOLOUN, SUPAPORN SUWIWAT and PARAMEE THONGSUKSAI

Departments of 1Biomedical Sciences and The Excellent Research Laboratory of Cancer Molecular Biology, 2Internal Medicine and 3Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand

Received February 27, 2016; Accepted July 7, 2017

DOI: 10.3892/ol.2017.6881

Abstract. Loss of 14-3-3-σ expression through DNA methylation has been associated with carcinogenesis and the prognosis for various cancer types. Detection of methylation of the gene in serum may be useful for diagnostic utility. The present study aimed to investigate the correlation between 14-3-3-σ methylation level in 36 paired tumor tissues of non-small cell lung cancer (NSCLC) and matched serum using methylation-specific polymerase chain reaction. The prognostic significance of 14-3-3-σ expression in 167 NSCLC was also evaluated using immunohistochemistry. Methylation of the 14-3-3-σ gene was identified in all samples. The methylation level in the serum (mean 87.7%, range 64.6-100%) was higher compared with tumor (mean 46.7%, range 25.3-56.3%). However, no significant correlation between methylation levels in tissues and serums was observed (Spearman’s correlation, -0.036; P=0.837). In the 167 tumor tissues, the majority of the cases (83.8%) exhibited negative expression. Adenocarcinoma is more likely to exhibit negative expression (91.4%) compared with squamous cell carcinoma (70.2%). No significant difference was identified in the overall survival according to 14-3-3-σ expression status and 14-3-3-σ expression did not demonstrated independent prognostic significance. In conclusion, NSCLC harbors certain levels of 14-3-3-σ methylation in the tumor and the sera of patients. The clinical value of serum 14-3-3-σ methylation should be further elucidated. Immunohistochemical expression 14-3-3-σ protein has limited value on prognostic significance.

Introduction

Lung cancer is the most common type of cancer among men worldwide, accounting for ~16.7% of all estimated new cancer cases (1). In Thailand, lung cancer is the second leading cancer in men with an age-standardized incidence rate of 27.1/100,000 (2). Approximately 85% of patients with lung cancer are diagnosed with non-small cell lung cancer (NSCLC). The survival of patients with lung cancer primarily depends on the stage of disease at the time of diagnosis. The 5-year survival rate of patients with early stage NSCLC is between 25 and 52%, while the rate is <4% for those with advanced stages (3). Although several advanced therapeutic modalities are available, the mortality rate remains high. Thus, identifying biological markers that are able to detect the disease at the early stage, or predict treatment response or prognosis is important for improving patient survival.

14-3-3 proteins are small acidic polypeptides that are 28-33 kDa in size, and consist of at least seven isoforms, β, v, γ, η, α, τ/0, and ξ, in mammalian cells. The proteins are spontaneously self-assembled to form homodimers or heterodimers and bind to various cellular proteins (4). The interaction between 14-3-3 proteins and other proteins has been demonstrated in a number of signaling pathways, including cell cycle progression, signal transduction, and apoptosis (5,6). Among the various isoforms, 14-3-3-σ is the most common isoform reported to be involved in carcinogenesis via a tumor suppression manner (7). Loss of 14-3-3-σ expression has been demonstrated in a variety of cancer types, particularly in adenocarcinoma-type tumors, including breast carcinoma (8) and gastric carcinoma (9). Subsequently, a number of these studies have demonstrated that epigenetic silencing through CpG methylation is responsible for the loss or reduction of 14-3-4-σ expression (10). With regards to prognosis, loss of expression of this protein has been reported to be associated with poor prognosis in ovarian and nasopharyngeal carcinoma (11,12). By contrast, poor overall survival in patients with high expression of 14-3-3-σ has been revealed in colorectal cancer, oral squamous cell carcinoma and gastric cancer (13-15).
In lung cancer, 14-3-3σ expression has been demonstrated to be abundantly expressed in cancerous tissue samples compared with normal lung tissues (16). In contrast with the results identified in breast cancer (8), it has been reported that 14-3-3σ expression is observed in the majority of lung adenocarcinoma (17) or NSCLC (18) tissues, and methylation is more frequently observed in small cell lung cancer compared with NSCLC (18). However, these findings have been reported in a few studies with a limited number of cases. In addition, there is little evidence to suggest that peripheral DNA sources reflect 14-3-3σ methylation in NSCLC tissue. In the present study, the association of 14-3-3σ methylation between tumor tissues and matched serum was investigated, and the prognostic value of 14-3-3σ expression was evaluated.

Materials and methods

Patients and specimens. Tissues and matched serum samples were obtained from 36 NSCLC patients who had not received any previous treatment. The obtained tissues were frozen immediately at -80°C for DNA extraction. For the matched serum samples, 10 ml peripheral blood was collected from the fore arm vein and kept at room temperature for 2 h. Serum was separated by double centrifugation at 1,600 x g for 10 min and kept at -80°C until analysis. All patients were diagnosed at Songklanagarind Hospital (Hat-Yai, Thailand), a university hospital in Southern Thailand, between May 2012 and April 2013. Fresh tumor tissue for methylation analysis was obtained via bronchial biopsy through bronchoscopy simultaneously when tissue was obtained for pathological diagnosis. Normal serum samples (n=7) were collected from healthy blood donors. Written informed consent was obtained from all patients. The mean age was 61 years (range, 32-83 years). Twenty-one patients were males and 15 were females. Seventeen cases were adenocarcinoma (ADC) and 15 cases were squamous cell carcinoma (SCC). The specific subtype was not specified in 4 cases, which were recorded as NSCLC-unclassified.

For the evaluation of prognostic significance of 14-3-3σ expression, 167 patients with stage I-IV of NSCLC who were diagnosed, and treated at Songklanagarind Hospital between January 2006 and December 2008 were included. The clinicopathological data, including the clinical stage were retrieved from the hospital registry data. Clinical staging was based on the Tumor Node Metastasis staging system of the International Union against Cancer (7th Edition) (19). The histological diagnosis was performed according to the WHO classification of lung and pleural tumors (2004) (20). The patients were followed up until September 2012. Data associated with the mortality of patients was obtained from the provincial nationwide-linked register of mortalities, where the law requires all mortalities that have occurred in Thailand to be registered within 24 h of occurrence. The present study was approved by the Ethics Committee on Human Research, Faculty of Medicine, and Prince of Songkla University (EC, 54-273-04-2-3 and 55-020-04-1-2).

Methylation-specific polymerase chain reaction (MSP). Genomic DNA was extracted from frozen tissue and serum samples using standard proteinase K/phenol/chloroform methods (21). The structural integrity of DNA was confirmed using 1% agarose gel electrophoresis and quantified with a spectrophotometer. The genomic DNA (1 µg) was subjected to sodium bisulfite modification using the EZ DNA Methylation-Gold kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's protocol. Modified DNA was resuspended in 15 µl of nuclease-free water, quantified using a spectrophotometer and stored at -70°C. For MSP analysis, the modified DNA (50 ng) was amplified using methylation or unmethylation primers spanning the region between CpG dinucleotides 3 and 9 of the 14-3-3σ gene. The primers were designed according to a previous report by Ferguson et al (8). Primers sequence were as follows: Methylation forward, 5'-GATATGGTAGTTTTATGAAA GGCCTCG-3' and reverse, 5'-CCTTACGCCCACACCAC G-3'; unmethylation forward, 5'-GATATGGTAGTTTT ATGAAAGGTGTGTGTG-3' and reverse, 5'-CCCTCTAAC CACCCACACA-3'. The MSP conditions maintained were as follows: 1 cycle at 94°C for 3 min; 35 cycles at 94°C for 30 sec, 64°C (methylated reaction) or 59°C (unmethylated reaction) for 30 sec, 72°C for 45 sec; and 1 cycle at 72°C 10 min. The MSP products were 108 and 109 bp for methylation, and unmethylation primers, respectively. Universal human methylated and unmethylated DNA strands (Zymo Research) were used as a positive control for each primer. Following amplification, the MSP products were separated on a 10% polyacrylamide gel, stained with ethidium bromide for 10 min at room temperature, visualized as bands under ultraviolet illumination and imaged using Gel Doc™ XR (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The density of bands was measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The relative density of each methylated and unmethylated products were obtained by dividing their values by the density of the corresponding positive control. The 14-3-3σ methylation level percentage was calculated as follows: Relative density of methylated products/relative density of methylated products + relative density of unmethylated products.

Immunohistochemistry. Sections 4 µm thick were cut from a paraffin-embedded block, deparaffinized with xylene and rehydrated with ethanol. Antigen retrieval was enhanced by rapid heating in a microwave in a citrate buffer (10 mM, pH 6.0) for 10 min. Endogenous peroxidase activity was blocked at room temperature by incubation with 3% hydrogen peroxide in methanol for 10 min. The slides were then incubated with 10% normal goat serum (Santa Cruz Biotechnology, Dallas, TX, USA) at room temperature for 20 min and incubated with monoclonal antibody against 14-3-3σ (5D7, sc-100,638; Santa Cruz Biotechnology) at a dilution of 1:800 overnight at 4°C in a humidified chamber. After washing with PBS (pH 7.4), the slides were incubated with a biotinylated goat anti-mouse IgG-B (sc-2039; Santa Cruz Biotechnology) at a dilution of 1:300 for 40 min at room temperature. Antigen-antibody complexes were detected using the avidin-biotin complex staining kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and a diaminobenzidine solution (Merck KGaA, Darmstadt, Germany) as a substrate for 5 min at room temperature. Finally, the slides were counterstained with hematoxylin for 5 min at room temperature (Santa Cruz Biotechnology),
cover slipped and examined under a light microscope at x200. Oral squamous carcinoma tissue from a patient with oral cancer was used as a positive control. Negative controls using the same tissue without primary antibody were run in parallel.

Evaluation of immunohistochemical staining. Immunoreactivity was qualitatively and quantitatively evaluated in terms of intensity, and percentage of positively stained cells, respectively. The intensity was scored as follows: 0, no staining; 1, weak; 2, moderate; and 3, intense. The percentage of positive cells was scored as follows: 0, ≤10%; 1, 11‑30%; 2, 31‑60%; and 3, ≥61%. Final scores (0‑9) were then obtained through multiplication of both scores. Four expression groups were assigned as follows: No expression, final score 0; weak expression, final score 1‑3; moderate expression, final score 4‑6; and strong expression, final score 7‑9. The expression of 14-3-3σ was dichotomized to give negative expression (final score 0) and positive expression (final score 1‑9).

Immunostaining was evaluated by two independent pathologists, and discordant cases was reevaluated and scored on the basis of consensus interpretation.

Statistical analysis. Methylation levels are presented as the mean ± standard deviation. The differences and correlation of methylation level between tumor, and matched serum were analyzed using a paired t-test and the Spearman correlation, respectively. The associations between 14-3-3σ expression and clinicopathological variables were analyzed using the chi-squared test. The survival rates according to 14-3-3σ expression status and other variables were examined using Kaplan-Meier analysis, and compared using the log-rank test. Cancer-associated mortality was considered to be the end event. The Cox multivariate proportional hazards model was used to identify independent prognostic variables. P<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using STATA software version 12.1 (StataCorp LP, College Station, TX, USA).

Results

14-3-3σ methylation in tumor and serum. Methylation of 14-3-3σ gene was identified in all samples. Representative methylated and unmethylated products of the samples run on the 10% polyacrylamide gel are presented in Fig. 1. The mean methylation level across all tumor tissues was 46.7% (range, 25.3‑69.2%). The methylation level in ADC (mean, 43.6%; range, 25.3‑56.3%) and SCC (mean, 48.6; range, 32.7‑68.6%) samples were comparable. The mean methylation level in patient sera was ~2 times higher compared with that of the primary tumors with a mean value of 87.7% (range, 64.6‑100%). However, the methylation levels in tissues and sera were not linearly correlated [Spearman's correlation (r), -0.036; P=0.837; Fig. 2]. The methylation level in normal serum (mean, 60.2%; range, 50.0‑75.0%) was lower compared with in patient sera.

Correlation between 14-3-3σ methylation and protein expression. The correlation between 14-3-3σ methylation and immunohistochemical protein expression was evaluated in 32 cases. The 14-3-3σ protein was primarily observed in the cytoplasm (Fig. 3) and 18 cases (56.2%) exhibited no expression. The remaining cases exhibited weak expression (7 cases,
RAUNGRUT et al. 14-3-3σ METHYLATION AND EXPRESSION IN NSCLC

21.9%) and moderate to strong expression (7 cases, 21.9%). No significant correlation was observed between immunohistochemical expression and the methylation level (r, 0.153; P=0.402).

Association between 14-3-3σ expression and clinicopathological variables. The immunohistochemical expression of 14-3-3σ protein in relation to clinicopathological characteristics and prognosis was evaluated in 167 patients. The patients had a mean age of 64 years (range, 37-93 years; Table I). The majority of patients exhibited the advanced stages of the disease (89.8%). The majority of the cases (140 cases, 83.8%) revealed no expression, whereas 19 (11.4%) and 8 (4.8%) cases demonstrated weak expression, and moderate/strong expression, respectively. Patients in the ADC group had a significantly higher frequency of no expression (91.4%) compared with SCC (70.2%) (P=0.002). In the further analysis, the weak to strong expression samples were grouped as positive expression. Sex and histological type were identified to be significantly associated with the expression status. In addition, tumors in males had a significantly higher frequency of positive expression compared with that of females (Table I).

Prognostic significance of 14-3-3σ expression. The patients had a median survival time of 5.7 months. The Kaplan-Meier estimates revealed no significant difference in overall survival according to 14-3-3σ expression status. Furthermore, no significant difference was identified in survival for ADC and SCC groups with P=0.13 and P=0.60, respectively (data not shown). Clinical stage, surgery, chemotherapy and histological type were associated with survival rates in the univariate analysis, but only age, and treatments were significant independent prognostic parameters in the multivariate analysis (Table II). 14-3-3σ expression did not exhibit prognostic significance.

Discussion

In recent years, the aberrant expression levels of the 14-3-3 protein family have been reported in various cancer types and as potential novel biological markers (4). Among various isoforms, 14-3-3σ is the most common isoform reported to be involved in carcinogenesis via a tumor suppressive manner (7). Loss of 14-3-3σ expression has been reported in various types of epithelial cancer and is reported to be associated with hypermethylation of the promoter of the gene (8-10). In the present study, the methylation status of the NSCLC tissue in relation to protein expression as well as in relation to the methylation level in their match serum was evaluated. The results revealed that all tumors harbored certain levels of methylation; however, it was not correlated with the level of protein expression. In addition, it was demonstrated that methylation level in serum was significantly higher compared with in primary tumor samples.

Hypermethylation of CpG islands is a well-known epigenetic mechanism for inactivating tumor suppressor genes, thus contributing significantly to tumor development (10,22). Methylation in the promoter region of the 14-3-3σ gene has been demonstrated in a high proportion of breast (90%) (23),
The results of the present study demonstrated that all NSCLC tumor samples harbored methylation in the promoter of 14-3-3σ gene (relative methylation level, 25.3-69.2%). The methylation status may be reported as partial methylation as methylated and unmethylated products were identified. These results are consistent with that of Shiba-Ishii and Noguchi (25) where invasive adenocarcinoma harbored partial methylation. SCC, in the present study, also revealed a comparable methylation level with ADC. However, these results were inconsistent with the study of Osada et al (18), whereby hypermethylation was identified to be frequent in small cell carcinoma cell lines, but rare in NSCLC cell lines.

It is well known that circulating cell-free DNA is released into the blood of patients with cancer, with increasing levels compared with normal healthy individuals (26), thus allowing for the detection of gene alternation of the primary tumor. Detection of hypermethylation in the promoter regions of certain tumor suppressor genes in the serum of patients with NSCLC was first reported by Esteller et al (27). Later, Ramirez et al (28) detected methylation in the sera of one-third of 115 advanced-stage patients with NSCLC. In the present study, a higher methylation level (mean, 87.7%) was observed in the serum of the patients compared with normal serum (mean, 60.2%). In addition, the serum methylation level was two to three times higher compared with the matched primary tumor samples and was not linearly correlated. The possible explanation is that the circulating DNA is contaminated by other sources, including inflammatory cells reacting to the tumor.

Table I. Correlation between 14-3-3σ expression and clinicopathological variables.

| Variable              | No. of cases | 14-3-3σ expression (%) | P-value |
|-----------------------|--------------|------------------------|---------|
|                       |              | Negative | Positive |         |
| Sex                   |              | 124      | 99 (79.8) | 25 (20.2) | 0.03   |
| Male                  | 43           | 9 (95.3)  | 2 (4.7)   |
| Female                |              | 63       | 55 (87.3) | 8 (12.7)  | 0.46   |
| Age, years            |              | 104      | 85 (81.7) | 19 (18.3) | 0.002  |
| <60                   | 57           | 40 (70.2) | 17 (29.8) |          |
| ≥60                   | 5            | 4 (80.0)  | 1 (20.0)  |          |
| Histological type     |              | 105      | 96 (91.4) | 9 (8.6)   | 0.38   |
| ADC                   | 57           | 40 (70.2) | 17 (29.8) |          |
| SCC                   | 5            | 4 (80.0)  | 1 (20.0)  |          |
| NSCLC-UC              |              | 105      | 96 (91.4) | 9 (8.6)   | 0.24   |
| Clinical stage        |              | 72       | 64 (88.9) | 8 (11.1)  | 0.93   |
| I                     | 10           | 8 (80)   | 2 (20)    |          |
| II                    | 5            | 3 (60)   | 2 (40)    |          |
| III                   | 59           | 51 (86.4) | 8 (13.6)  |          |
| IV                    | 9            | 77 (84.6) | 14 (15.4) |          |
| Unknown               | 2            | 1 (50)   | 1 (50)    |          |
| LN metastasis         |              | 157      | 132 (84.1)| 25 (15.9) | 0.92   |
| No                    | 72           | 64 (88.9) | 8 (11.1)  |          |
| Yes                   | 95           | 76 (80)  | 19 (20)   |          |
| Distant metastasis    |              | 76       | 63 (82.9) | 13 (17.1) | 0.22   |
| No                    | 157          | 132 (84.1)| 25 (15.9) |          |
| Yes                   | 10           | 8 (80)   | 2 (20)    |          |
| Surgery               |              | 87       | 70 (80.5) | 17 (19.5) | 0.14   |
| No                    | 80           | 70 (87.5) | 10 (12.5) |          |
| Yes                   | 116          | 101 (87.1)| 15 (12.9) |          |
| Chemotherapy          |              | 51       | 39 (76.5) | 12 (23.5) | 0.14   |
| No                    | 51           | 39 (76.5) | 12 (23.5) |          |
| Yes                   |              | 101 (87.1)| 15 (12.9) |          |

ADC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC-UC, non-small cell lung cancer-unclassified; LN, lymph node.

nasopharynx (84%) (24), ovary, endometrium and prostate (11) carcinoma. The results of the present study demonstrated that all NSCLC tumor samples harbored methylation in the promoter of 14-3-3σ gene (relative methylation level, 25.3-69.2%). The methylation status may be reported as partial methylation as methylated and unmethylated products were identified. These results are consistent with that of Shiba-Ishii and Noguchi (25) where invasive adenocarcinoma harbored partial methylation. SCC, in the present study, also revealed a comparable methylation level with ADC. However, these results were inconsistent with the study of Osada et al (18), whereby hypermethylation was identified to be frequent in small cell carcinoma cell lines, but rare in NSCLC cell lines.

It is well known that circulating cell-free DNA is released into the blood of patients with cancer, with increasing levels compared with normal healthy individuals (26), thus allowing for the detection of gene alternation of the primary tumor. Detection of hypermethylation in the promoter regions of certain tumor suppressor genes in the serum of patients with NSCLC was first reported by Esteller et al (27). Later, Ramirez et al (28) detected methylation in the sera of one-third of 115 advanced-stage patients with NSCLC. In the present study, a higher methylation level (mean, 87.7%) was observed in the serum of the patients compared with normal serum (mean, 60.2%). In addition, the serum methylation level was two to three times higher compared with the matched primary tumor samples and was not linearly correlated. The possible explanation is that the circulating DNA is contaminated by other sources, including inflammatory cells reacting to the tumor. The inflammatory process
has been demonstrated to serve a role in the pathogenesis of NSCLC and the majority of lung cancer cases coexist with inflammatory reactions (29). In addition, lysis of peripheral blood lymphocytes during serum separation may cause an artificial increase in DNA (30). However, this risk was minimized by performing centrifugation of the collected serum within 2 h.

Methylation of the promoter region of genes is typically associated with decreased or a loss of protein expression. Shiba-Ishii and Noguchi (25) identified an inverse correlation between the level of the 14-3-3σ transcript and methylation level in lung adenocarcinoma tissue. By contrast, no significant correlation was identified in the present study. Similarly, no significant correlation between the methylation of the 14-3-3σ gene in the tumor and protein expression was noted in the study of Osada et al (18). The authors demonstrated that certain SCLC tissues exhibited almost complete unmethylation of the 14-3-3σ gene as indicated by the loss of protein expression. This may indicate that 14-3-3σ protein expression is affected by additional mechanisms. Furthermore, clinical tissue specimen may be contaminated by other cells/tissue, including stromal cells or inflammatory cells as reported by Osada et al (18), whereby it was demonstrated that microdissected stromal tissue also harbored 14-3-3σ hypermethylation.

Previous studies regarding the expression of 14-3-3σ in NSCLC are conflicting. Osada et al (18) reported immunohistochemical expression of 14-3-3σ in 21/22 NSCLC specimens and Shiba-Ishii et al (17) observed immunopositive staining in 95% of ADC. By contrast, Liu et al (31) observed the downregulation of 14-3-3σ in NSCLC cell lines. The present study demonstrated that the majority of NSCLC (84%) demonstrated no expression of 14-3-3σ following immunohistochemistry, which is consistent with the results of studies on other cancer types, in particular breast (8) and prostate (32) cancer. The number of specimens examined may contribute to the contradictory results in lung cancer.

Table II. Univariate and multivariate analysis of clinicopathological variables for overall survival.

| Variable                  | Univariate analysis | Multivariate analysis |
|---------------------------|---------------------|-----------------------|
|                           | Risk ratio (95% CI) | P-value               | Risk ratio (95% CI) | P-value               |
| Sex                       | 0.339               |                       | 0.031               |                       |
| Male                      | 1                   |                       |                     |                      |
| Female                    | 0.85 (0.61-1.19)    |                       |                     |                      |
| Age, years                |                     |                       | 0.69 (0.50-0.97)    |                       |
| <60                       | 1                   |                       | 0.69 (0.50-0.97)    |                       |
| ≥60                       | 1.08 (0.79-1.48)    |                       |                     |                      |
| Histological type         | 0.022               |                       |                     |                      |
| ADC                       | 1                   |                       |                     |                      |
| SCC                       | 1.27 (0.93-1.74)    |                       |                     |                      |
| NSCLC-UC                  | 3.9 (1.56-9.76)     |                       |                     |                      |
| Clinical stage            | <0.001              | <0.001                | <0.001              | <0.001                |
| I                         | 1                   |                       |                     |                      |
| II                        | 6.19 (1.47-26.11)   |                       |                     |                      |
| III                       | 9.02 (2.79-29.10)   |                       |                     |                      |
| IV                        | 9.62 (3.00-30.87)   |                       |                     |                      |
| Unknown                   | 52.6 (10.17-272.16) |                       |                     |                      |
| Surgery                   | <0.001              | <0.001                | <0.001              | <0.001                |
| No                        | 1                   |                       |                     |                      |
| Yes                       | 0.09 (0.03-0.28)    |                       | 0.06 (0.02-0.20)    |                       |
| Chemotherapy              | <0.001              | <0.001                | <0.001              | <0.001                |
| No                        | 1                   |                       |                     |                      |
| Yes                       | 0.5 (0.37-0.68)     |                       | 0.47 (0.33-0.66)    |                       |
| Radiotherapy              | 0.069               |                       | 0.015               |                       |
| No                        | 1                   |                       |                     |                      |
| Yes                       | 0.75 (0.55-1.03)    |                       | 0.66 (0.47-0.92)    |                       |
| 14-3-3σ expression        | 0.248               |                       |                     |                      |
| Negative                  | 1                   |                       |                     |                      |
| Positive                  | 1.44 (0.95-2.19)    |                       |                     |                      |

CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma; NSCLC-UC, non-small cell lung cancer-unclassified.
Regarding the prognostic role, the decreased expression of 14-3-3σ has been reported to be correlated with a short survival rate in esophageal squamous cell carcinoma (33) and ovarian cancer (33,34), and a good survival rate in gastric cancer (35). However, the present study did not identify prognostic significance of 14-3-3σ expression in NSCLC. This may possibly be due to the small numbers of patients with a positive expression. In addition, the majority of the patients had stage III-IV cancer, thus the insignificance may also be due to the homogeneity of cases regarding of stage of disease.

In conclusion, the results of the present study have demonstrated that NSCLC harbored partial 14-3-3σ methylation and may, in part, contribute to the loss of protein expression in the tumor. The serum of patients with advanced NSCLC exhibited a high level of 14-3-3σ methylation, but its clinical value remains to be elucidated. The prognostic significance of immunohistochemical expression of the protein was not demonstrated, possibly due to the small number of cases with positive expression and homogeneity of advanced cases.

Acknowledgements

The present study was supported by the Prince of Songkla University (grant no. MED5406775) and Faculty of Medicine, Songkhla, Thailand (grant no. 540200412). The Excellent Research Laboratory of Cancer Molecular Biology was acknowledged for research facilities.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Attasara P and Srilung H: Cancer incidence in Thailand. In: Cancer in Thailand Volume VI, 2004-2006. Khluaprema T, Attasara P, Srilung H, Wiangnon S, Sumitsawan Y and Sangrajaraj S (eds). National Cancer Institute (Thailand), Bangkok, pp3-68, 2012.
3. National Cancer Institute: SEER Cancer Statistics Review, 1975-2012. http://seer.cancer.gov/csr/1975_2012/. Accessed April, 2015.
4. Aitken A: 14-3-3 proteins: A historic overview. Semin Cancer Biol 16: 162-172, 2006.
5. Galan JA, Geraghty KM, Lavoie G, Kanshin E, Tcherkezian J, Calabrese V, Jesche GR, Turk BE, Ballif BA, Blenis J, et al.: Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3. Proc Natl Acad Sci USA 111: E2918-E2927, 2014.
6. Dar A, Wu D, Lee N, Shibata E and Dutta A: 14-3-3 proteins play a role in the cell cycle by shielding cd2t2 from ubiquitin-mediated degradation. Mol Cell Biol 34: 4049-4061, 2014.
7. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B: 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3-11, 1997.
8. Ferguson AT, Etron V, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Furteal PA, Stamper MR and Sukumar S: High frequency of hypermethylation at the 14-3-3σ gene locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000.
9. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakuchi H and Imai K: Inactivation of the 14-3-3σ gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
10. Lodging D and Hermeking H: The role of epigenetic inactivation of 14-3-3σ in human cancer. Cell Res 15: 237-346, 2005.
11. Mhawech P, Grelov Z, Assaly M and Herrmann F: Immunohistochemical expression of 14-3-3σ protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol Int 55: 77-82, 2005.
12. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al.: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 2020-2026, 2008.
13. Perathoner A, Pirklebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R and Amberger A: 14-3-3σ gene methylation is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11: 3274-3279, 2005.
14. Laimer K, Blassnigg N, Spizzo G, Kloss F, Rasse M, Obrist P, Schäfer G, Perathoner A, Margreiter R and Amberger A: Prognostic significance of 14-3-3σ gene expression in oral squamous cell carcinoma (OSCC). Oral Oncol 45: 127-134, 2009.
15. Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, Lin DJ, Shao CK and Liu Q: Aberrant methylation of 14-3-3σ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 11: 397, 2011.
16. Qi W, Liu X, Qiao D and Martinez JD: Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer 113: 359-63, 2005.
17. Shibai-Shissi A, Kano J, Morishita Y, Sato Y, Minami Y and Noguchi M: High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. Int J Cancer 129: 2445-2453, 2011.
18. Osaka H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M and Takahashi F: Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers. Oncogene 21: 2418-2424, 2002.
19. International Union Against Cancer (UICC): TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK and Wittekind CH (eds). 7th edition. Wiley-Blackwell, Hoboken, NJ, 2009.
20. Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 3rd edition. IARC Press, Lyon, pp45-pp975, 2004.
21. Green MR and Sambrook J: Molecular cloning. A laboratory manual. 4th edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2012.
22. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Cancer 3: 415-428, 2002.
23. Luo J, Feng J, Lu J, Wang Y, Tang X, Xie F and Li W: Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis. Med Oncol 27: 791-797, 2010.
24. Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, Zhang PF, Li MY, Li JL, Yi H, et al.: Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem 106: 858-866, 2009.
25. Shibai-Ishii A and Noguchi M: Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung gland adenocarcinoma. Am J Pathol 180: 1653-1662, 2012.
26. Gormanally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, Dunning A, Gatteschi S, Matullo G, Verhaegen P, et al.: Amount of DNA in plasma and cancer risk: A prospective study. Int J Cancer 111: 744-749, 2004.
27. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67-70, 1999.
28. Rodriguez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola Y, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, et al.: 14-3-3σ gene methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 23: 9105-9112, 2005.
29. Jiyihävi J, Jyihäi M, Lehtimäki T, Hervonen A and Hurme M: Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: The Vitality 90+ Study. Exp Gerontol 47: 372-378, 2012.
30. Umetani N, Kim J, Hiramoto S, Reber HA, Hines OJ, Bilchik AJ and Hoon DS: Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats. Clin Chem 52: 1062-1069, 2006.
31. Liu Y, Chen Q and Zhang JT: Tumor suppressor gene 14-3-3σ is under-regulated whereas the proto-oncogene translation elongation factor Idelta is up-regulated in non-small cell lung cancers as identified by proteomic profiling. J Proteome Res 3: 728-735, 2004.

ONCOLOGY LETTERS 14: 5257-5264, 2017 5263
32. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, et al: Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res 10: 3064-3068, 2004.

33. Ren HZ, Pan GQ, Wang JS, Wen JF, Wang KS, Luo GQ and Shan XZ: Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Dig Dis Sci 55: 2552-2560, 2010.

34. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation. Clin Cancer Res 10: 2687-3793, 2004.

35. Li YL, Liu L, Xiao Y, Zeng T and Zeng C: 14-3-3σ is an independent prognostic biomarker for gastric cancer and is associated with apoptosis and proliferation in gastric cancer. Oncol Lett 9: 290-294, 2015.